<?xml version='1.0' encoding='utf-8'?>
<document id="31728714"><sentence text="The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants."><entity charOffset="14-26" id="DDI-PubMed.31728714.s1.e0" text="itraconazole" /><entity charOffset="54-64" id="DDI-PubMed.31728714.s1.e1" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31728714.s1.e0" e2="DDI-PubMed.31728714.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31728714.s1.e0" e2="DDI-PubMed.31728714.s1.e1" /></sentence><sentence text="Background The third-generation tyrosine kinase inhibitor lorlatinib is approved for the treatment of ALK-positive metastatic NSCLC"><entity charOffset="32-40" id="DDI-PubMed.31728714.s2.e0" text="tyrosine" /><entity charOffset="58-68" id="DDI-PubMed.31728714.s2.e1" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31728714.s2.e0" e2="DDI-PubMed.31728714.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31728714.s2.e0" e2="DDI-PubMed.31728714.s2.e1" /></sentence><sentence text=" CYP3A plays a major role in lorlatinib metabolism; therefore, a drug-drug interaction study was warranted to evaluate the impact of the strong CYP3A inhibitor, itraconazole, on lorlatinib plasma exposure"><entity charOffset="161-173" id="DDI-PubMed.31728714.s3.e0" text="itraconazole" /><entity charOffset="178-188" id="DDI-PubMed.31728714.s3.e1" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31728714.s3.e0" e2="DDI-PubMed.31728714.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31728714.s3.e0" e2="DDI-PubMed.31728714.s3.e1" /></sentence><sentence text=" Methods This phase 1, open-label, 2-period, crossover study estimated the effects of itraconazole on the plasma pharmacokinetics and safety of lorlatinib in healthy participants (NCT02838264)"><entity charOffset="86-98" id="DDI-PubMed.31728714.s4.e0" text="itraconazole" /><entity charOffset="144-154" id="DDI-PubMed.31728714.s4.e1" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31728714.s4.e0" e2="DDI-PubMed.31728714.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31728714.s4.e0" e2="DDI-PubMed.31728714.s4.e1" /></sentence><sentence text=" Single-dose lorlatinib 50 mg (n = 2), 75 mg (n = 2) and 100 mg (n = 12) was administered in Period 1"><entity charOffset="13-23" id="DDI-PubMed.31728714.s5.e0" text="lorlatinib" /></sentence><sentence text=" In Period 2, itraconazole oral solution 200 mg/day was administered on Days 1-11, and single-dose lorlatinib on Day 5"><entity charOffset="99-109" id="DDI-PubMed.31728714.s6.e0" text="lorlatinib" /></sentence><sentence text=" Blood samples were collected up to 168 h after lorlatinib dosing"><entity charOffset="48-58" id="DDI-PubMed.31728714.s7.e0" text="lorlatinib" /></sentence><sentence text=" Results During daily dosing with itraconazole (Period 2), the ratios of the adjusted geometric means for area under the plasma concentration-time profile extrapolated to infinity (AUCinf) and maximum plasma concentration (Cmax) of single-dose lorlatinib 100 mg were 141"><entity charOffset="34-46" id="DDI-PubMed.31728714.s8.e0" text="itraconazole" /><entity charOffset="244-254" id="DDI-PubMed.31728714.s8.e1" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31728714.s8.e0" e2="DDI-PubMed.31728714.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31728714.s8.e0" e2="DDI-PubMed.31728714.s8.e1" /></sentence><sentence text="79% (90% confidence interval, 128" /><sentence text="71%, 156" /><sentence text="21%) and 124" /><sentence text="39% (110" /><sentence text="20%, 140" /><sentence text="41%), respectively, compared with Period 1 (lorlatinib alone)" /><sentence text=" Lorlatinib was well tolerated alone and with itraconazole"><entity charOffset="1-11" id="DDI-PubMed.31728714.s15.e0" text="Lorlatinib" /><entity charOffset="46-58" id="DDI-PubMed.31728714.s15.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.31728714.s15.e0" e2="DDI-PubMed.31728714.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31728714.s15.e0" e2="DDI-PubMed.31728714.s15.e1" /></sentence><sentence text=" No serious adverse events or withdrawals were reported" /><sentence text=" Conclusions Co-administration of itraconazole and lorlatinib increased the plasma exposure of lorlatinib relative to lorlatinib alone in healthy participants"><entity charOffset="34-46" id="DDI-PubMed.31728714.s17.e0" text="itraconazole" /><entity charOffset="51-61" id="DDI-PubMed.31728714.s17.e1" text="lorlatinib" /><entity charOffset="95-105" id="DDI-PubMed.31728714.s17.e2" text="lorlatinib" /><pair ddi="false" e1="DDI-PubMed.31728714.s17.e0" e2="DDI-PubMed.31728714.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31728714.s17.e0" e2="DDI-PubMed.31728714.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31728714.s17.e0" e2="DDI-PubMed.31728714.s17.e2" /><pair ddi="false" e1="DDI-PubMed.31728714.s17.e1" e2="DDI-PubMed.31728714.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31728714.s17.e1" e2="DDI-PubMed.31728714.s17.e2" /></sentence><sentence text=" Therefore, concomitant use of lorlatinib with strong CYP3A inhibitors should be avoided"><entity charOffset="31-41" id="DDI-PubMed.31728714.s18.e0" text="lorlatinib" /></sentence><sentence text=" If this combination is unavoidable, the starting dose of lorlatinib should be reduced from 100 mg to 75 mg"><entity charOffset="58-68" id="DDI-PubMed.31728714.s19.e0" text="lorlatinib" /></sentence><sentence text="" /></document>